- Home
- OFS vs KYTX Comparison
OFS vs KYTX Comparison
Compare OFS & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OFS
- KYTX
- Stock Information
- Founded
- OFS 2001
- KYTX 2018
- Country
- OFS United States
- KYTX United States
- Employees
- OFS N/A
- KYTX N/A
- Industry
- OFS Finance/Investors Services
- KYTX
- Sector
- OFS Finance
- KYTX
- Exchange
- OFS Nasdaq
- KYTX NYSE
- Market Cap
- OFS 127.4M
- KYTX 125.2M
- IPO Year
- OFS 2012
- KYTX 2024
- Fundamental
- Price
- OFS $8.44
- KYTX $1.86
- Analyst Decision
- OFS
- KYTX Buy
- Analyst Count
- OFS 0
- KYTX 5
- Target Price
- OFS N/A
- KYTX $18.80
- AVG Volume (30 Days)
- OFS 65.4K
- KYTX 295.7K
- Earning Date
- OFS 05-01-2025
- KYTX 05-13-2025
- Dividend Yield
- OFS 16.23%
- KYTX N/A
- EPS Growth
- OFS N/A
- KYTX N/A
- EPS
- OFS 2.12
- KYTX N/A
- Revenue
- OFS $47,964,000.00
- KYTX N/A
- Revenue This Year
- OFS N/A
- KYTX N/A
- Revenue Next Year
- OFS N/A
- KYTX N/A
- P/E Ratio
- OFS $3.95
- KYTX N/A
- Revenue Growth
- OFS N/A
- KYTX N/A
- 52 Week Low
- OFS $7.75
- KYTX $1.79
- 52 Week High
- OFS $10.04
- KYTX $22.44
- Technical
- Relative Strength Index (RSI)
- OFS 45.38
- KYTX 39.01
- Support Level
- OFS $8.15
- KYTX $1.81
- Resistance Level
- OFS $8.60
- KYTX $2.27
- Average True Range (ATR)
- OFS 0.42
- KYTX 0.21
- MACD
- OFS -0.07
- KYTX 0.02
- Stochastic Oscillator
- OFS 34.15
- KYTX 16.33
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.